Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
2019
Triglyceride elevation has re-emerged as a potent marker of residual cardiovascular risk in statin-treated patients [(1)][1]. Converging lines of evidence from epidemiological analyses, Mendelian randomization studies, and outcome data from REDUCE-IT (Reduction of Cardiovascular Events with EPA-
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
48
Citations
NaN
KQI